Copaxone
FDA Issues Boxed Warning for Anaphylaxis Risk with Multiple Sclerosis Drugs Copaxone and Glatopa
FDA, boxed warning, anaphylaxis, multiple sclerosis, Copaxone, Glatopa, glatiramer acetate, Teva, Sandoz
FDA Adds Boxed Warning to Teva’s Copaxone and Generic Glatopa Due to Anaphylaxis Risk
FDA Boxed Warning, Anaphylaxis Risk, Copaxone, Glatopa, Glatiramer Acetate, Multiple Sclerosis (MS) Treatment, Allergic Reaction
European Commission Imposes €463 Million Fine on Teva for Anti-Competitive Practices in MS Drug Market
Teva, European Commission, fine, MS drug, competition tactics, Copaxone, market dominance
Teva Pharmaceuticals Agrees to $450M Settlement Over Kickback and Price-Fixing Allegations
Teva Pharmaceuticals, False Claims Act, Anti-Kickback Statute, price-fixing, kickbacks, settlement, generic drugs, Medicare, Copaxone